Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Holdings Lowered by Vontobel Holding Ltd.

Vontobel Holding Ltd. trimmed its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 31.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,502 shares of the company’s stock after selling 2,483 shares during the period. Vontobel Holding Ltd.’s holdings in Ionis Pharmaceuticals were worth $220,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in IONS. TD Asset Management Inc boosted its stake in shares of Ionis Pharmaceuticals by 6.1% during the 2nd quarter. TD Asset Management Inc now owns 952,762 shares of the company’s stock worth $45,409,000 after acquiring an additional 54,400 shares in the last quarter. Candriam S.C.A. boosted its position in shares of Ionis Pharmaceuticals by 4.0% in the 2nd quarter. Candriam S.C.A. now owns 948,266 shares of the company’s stock valued at $45,192,000 after purchasing an additional 36,369 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in shares of Ionis Pharmaceuticals by 12.2% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 571,763 shares of the company’s stock valued at $24,786,000 after purchasing an additional 62,230 shares during the period. Great Point Partners LLC purchased a new position in Ionis Pharmaceuticals in the 2nd quarter worth about $15,728,000. Finally, Logos Global Management LP acquired a new stake in Ionis Pharmaceuticals during the 2nd quarter worth about $14,298,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ:IONS opened at $38.42 on Thursday. Ionis Pharmaceuticals, Inc. has a 1 year low of $35.95 and a 1 year high of $54.44. The firm has a fifty day moving average price of $42.74 and a 200 day moving average price of $43.15. The company has a current ratio of 7.61, a quick ratio of 7.51 and a debt-to-equity ratio of 4.67. The stock has a market capitalization of $5.61 billion, a PE ratio of -14.39 and a beta of 0.38.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.47. Ionis Pharmaceuticals had a negative return on equity of 115.66% and a negative net margin of 44.90%. The company had revenue of $225.00 million during the quarter, compared to the consensus estimate of $152.35 million. During the same quarter in the prior year, the company posted $0.60 EPS. The firm’s revenue was up 19.7% on a year-over-year basis. Analysts expect that Ionis Pharmaceuticals, Inc. will post -3.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IONS. TD Cowen lifted their target price on shares of Ionis Pharmaceuticals from $54.00 to $59.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Leerink Partnrs upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 24th. Bank of America increased their target price on Ionis Pharmaceuticals from $67.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. BMO Capital Markets downgraded Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $67.00 to $60.00 in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. upped their price target on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $60.28.

Insider Buying and Selling at Ionis Pharmaceuticals

In other news, EVP Richard S. Geary sold 2,430 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $48.00, for a total value of $116,640.00. Following the completion of the sale, the executive vice president now directly owns 85,508 shares in the company, valued at approximately $4,104,384. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 2,803 shares of company stock worth $134,402 over the last 90 days. Insiders own 2.71% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.